Platinum Pharmaceuticals and the University of Ulysses announced a licensing agreement with AbbVie for the new coronary antibody and launched clinical trials

On December 15, 2020, Global Biopharmaceuticals and Platinum Pharmaceuticals (stock code: 02142. HK) and the University of Utrecht announced that ABBV-47D11, an all-human source and antibody authorized by AbbVie for COVID-19 and related coronavirus prevention and treatment, has conducted a phase I clinical trial.
AbbVie will start the clinical research project in the United States and expand to Europe.
and platinum pharmaceutical H2L2 all-human genetically modified mouse platform can quickly identify and develop effective drug candidates, of which the cross-reactive neutrality of ABBV-47D11 makes it an ideal candidate for this drug.
the antibody targets the conservative region of SARS-CoV-2, and to date, cooperative preclinical studies have shown that antibodies against this target have good therapeutic potential for current outbreaks, including a range of potential escape mutations.
the signing of the license agreement will help facilitate the development of the ABBV-47D11.
in preclinical studies, the antibody showed the potential to block SARS-CoV-2 and SARS-CoV-1 infections.
under the equity introduction agreement, AbbVie will be responsible for the clinical study of ABBV-47D11 and, if successful, for the global production and commercialization process.
at the same time, AbbVie will pay a one-time equity transfer fee and a phased fee for the development, regulation and sale of the antibody's equity to Platinum Pharmaceuticals and the University of Ulysses, as well as a tiered royalty on net commercial sales.
university medical center in Therasmus was involved in the basic science section of the study and did not participate in the signing of the authorization agreement.
remaining terms have not been disclosed.
Phase I clinical trial will be a randomized, double-blind, placebo-controlled study designed to assess the safety, pharmacodynamics, and pharmacodynamics of ABBV-47D11 in a single dose climb in COVID-19 adult hospitalized populations.
the trial will be tested in three dose groups on 24 patients spread across multiple research bases around the world, with the main endpoint of evaluating drug-related adverse events and setting up multiple secondary endpoints. "The rapid progress of this project depends on the strengths of our outstanding research and development team and university partners, as well as the strengths of platinum medicine's all-human antibody discovery platform, as well as our partner AbbVie's global expertise in antibody and antiviral drug development," said Dr. Wang Jinsong, Principal Founder, Executive Director, Chairman and CEO of
and Platinum Pharmaceuticals.
with the clinical trial of the project, we hope to provide a new treatment for the current outbreak.
"()